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The estrogen receptor and human epidermal growth
factor receptor (HER) signaling pathways are the
dominant drivers of cell proliferation and survival in
the majority of human breast cancers. Not surprisingly,
targeting these pathways provides the most effective
therapies in appropriately selected patients. However,
de novo and acquired resistance remain major
obstacles to successful treatment. By increasing the
understanding of the molecular mechanisms of
combined HER2-targeted therapies, we aim to be
better able to select patients who would respond to
these treatments and understand some of the
mechanisms of resistance to HER2-targeted treatments.
Recent studies have demonstrated an increased
effectiveness of dual targeted HER2 therapies against
HER2-amplified breast cancer as compared with single
blockade. These studies have resulted in the recent
US Food and Drug Administration approval of the
combination of taxane chemotherapy with pertuzumab
and trastuzumab in the first-line metastatic setting as
well as an accelerated approval in the neoadjuvant
setting. Another mechanism for overcoming resistance
to HER2 targeted therapies is the antibody–drug
conjugate trastuzumab–emtansine, which targets the
HER2 receptor conjugated to the potent antimicrotubule
agent mertansine, allowing for intracellular release of the
cytotoxic drug. Studies evaluating the efficacy of dual
blockade with antibody–drug conjugate are currently
ongoing. This article reviews recent data on different
combinations of anti-HER2 treatments as well as ongoing
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Recognition of the impact of human epidermal growth
factor receptor (HER)-2 overexpression or amplification
in approximately 15 to 20% of all cases of invasive breast
cancer has resulted in the development of multiple drugs
that inhibit the proliferative signal pathway associated
with this molecular alteration. The incorporation of
HER2-directed therapy has improved the overall survival
(OS) of metastatic breast cancer (MBC) patients by greater
than 20% and has increased the cure rate of breast cancer
in the adjuvant setting by approximately 30 to 40% [1,2].
Despite this, approximately 5,000 patients with HER2-
overexpressing breast cancer die each year in the USA [3].
The HER family of transmembrane type I receptor
tyrosine kinases includes four receptors (HER1 to HER4)
that play an important role in cell processes including
cell proliferation and survival. HER2 does not require lig-
and activation and can form homodimers or can interact
with the other HER family receptors by forming heterodi-
mers that lead to the activation of the HER2 tyrosine kin-
ase. HER3 has only a weak intrinsic tyrosine kinase
activity that activates HER2 by forming heterodimers with
HER2, leading to the strongest preclinical mitogenic sig-
nals of all possible HER receptor dimer combinations [4].
Upon ligand binding to the active domain of HER1,
HER3 or HER4, these receptors can activate homodi-
meric or heterodimeric receptor complexes – but they
preferentially recruit HER2 into a heterodimeric complex
in which the HER2 kinase can modulate receptor internal-
ization and prolong signal transduction. Conformational
changes occur upon dimerization, leading to autophos-
phorylation and initiation of divergent signal transduc-
tion cascades [5]. These signaling pathways from these
some of their functions may overlap; laboratory data
generally indicate that HER1/HER2 heterodimers activate
cell proliferation by the extracellular signal-regulated
kinase 1/2–mitogen-activated protein kinase pathway [6],
while HER2/HER3 heterodimers predominantly activate
the phosphoinositide-3-kinase (PI3K)/AKT cell survival
pathway [7].d. The licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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of HER2-positive breast cancer
Several drugs have been developed and are in clinical
use to block the HER pathway, most aimed at the recep-
tor level.
Trastuzumab, a monoclonal antibody directed against
HER2, became the first HER2-directed therapy for MBC
and the first monoclonal antibody against cancer ap-
proved by the US Food and Drug Administration (FDA)
in 1998 [2]. Trastuzumab has been theorized to induce
cell death in HER2-overexpressing breast cancer cells by
multiple mechanisms including antibody-dependent cell-
mediated cytotoxicity, induction of apoptosis and inacti-
vation of HER2-mediated cell proliferation signaling [3].
A phase III clinical trial showed the effectiveness of tras-
tuzumab in synergizing with chemotherapy by increasing
the response rate and improving the OS of patients
with MBC when compared with chemotherapy alone
[2]. Trastuzumab is also commonly used in the refractory
metastatic setting in combination with a wide range of
chemotherapy agents. Use of trastuzumab is also pivotal
to patient management in the adjuvant setting, as it im-
proves disease-free survival (DFS) and OS when added to
chemotherapy [1].
Lapatinib is an orally active dual HER1/HER2 kinase in-
hibitor that blocks signal transduction pathways. Lapatinib
reduces tyrosine phosphorylation of HER1 and HER2, as
well as activation of extracellular signal-regulated kinase
1/2–mitogen-activated protein kinase and PI3K/AKT,
affecting downstream effectors of both proliferation and
survival [8]. Lapatinib has demonstrated activity in pa-
tients with HER2-overexpressing MBC after escape from
trastuzumab and is currently approved as second-line
therapy for MBC patients after trastuzumab failure [9,10].
However, comparative phase III trials of chemotherapy
with either trastuzumab or lapatinib suggested that trastu-
zumab was the optimal anti-HER2 therapy to select in this
first-line MBC setting.
Pertuzumab, a recombinant humanized monoclonal
antibody (2C4), binds to extracellular domain II of the
HER2 receptor and blocks its ability to dimerize with
other HER receptors, in particular HER2–HER3 com-
plexes [11]. Pertuzumab was approved in combination
with chemotherapy and trastuzumab for the first-line
treatment of HER2-positive MBC and for the neoadju-
vant therapy of HER2-positive breast cancer, based on
data demonstrating improvement in progression-free
survival and OS as compared with trastuzumab-based
chemotherapy in patients with MBC and a higher rate of
pathological complete remissions in the neoadjuvant
setting [12].
In addition to these receptor targeted therapies, a new
class of antibody–drug conjugate (ADC) has recently shown
superior clinical activity. Ado-trastuzumab-emtansine(T-DM1) is an ADC that incorporates the HER2-tar-
geted antitumor properties of trastuzumab with the
cytotoxic activity of the microtubule-inhibitory agent
mertansine (derivative of maytansine); the antibody
and the cytotoxic agent are conjugated by means of a
unique stable linker. T-DM1 allows intracellular drug
delivery specifically to HER2-overexpressing cells, thereby
improving the therapeutic index and minimizing exposure
of normal tissue. T-DM1 has demonstrated survival and
superior tolerability over the lapatinib/capecitabine com-
bination in the refractory HER2-positive advanced setting,
and has received regulatory agency approval for such
situations [13,14].
Table 1 presents the pivotal trials leading to US FDA
approval of the different drugs targeting HER2 and the
different approved combinations. This approval has con-
verted a disease that had the worst prognosis of all breast
cancer subtypes into one with the best prognosis. Of inter-
est is the fact that only a minority of breast cancer cases
(20%) benefit from these treatments, which implies that
these treatments may not have been proven to be of bene-
fit if they had been applied to all breast cancer patients
instead of being limited to the HER2-amplified subset,
illustrating the importance of appropriate patient subset
selection based on the biology of the tumor for successful
drug discovery and development.
Despite the success of these agents that target the
HER family as single agents, there are a number of escape
mechanisms from HER-targeted therapies. Clinically, a
more complete blockade of the HER receptor layer has
been shown to be therapeutically meaningful in prolong-
ing survival in patients. With incomplete blockade of the
receptor input layer, proliferative and survival signals can
be generated from several different dimer pairs. The idea
that the redundancy in the input layer of the network
might provide an escape mechanism around a single-
agent block has been explored in preclinical trials and
neoadjuvant trials as well as in adjuvant trials. Dual HER2
blockade is defined as a more complete blockade of the
HER2 and HER signaling pathway by combining two in-
hibitors with complementary mechanisms of action. In this
article, we will review the data supporting these find-
ings and the plans for further evaluation of dual HER2
blockade.
Why is dual HER2 blockade more effective than
single-drug blockade: causes of resistance to
single-agent HER2 blockade
Despite the success in MBC, responses to single-agent
trastuzumab are limited and cancer will eventually pro-
gress. Many patients treated with adjuvant trastuzumab
will be cured of the disease, but disease will recur in some
of them. This suggests that both de novo and acquired
mechanisms of drug resistance exist. Several possible
Table 1 Chronological summary of US Food and Drug Administration approved anti-HER2 treatments in HER2-amplified
breast cancer
Year of approval Cancer stage Agent Study name Chemotherapy
1998 [2] First-line metastatic T – Pac or AC
1998 [2] Second-line and third-line metastatic T – None
2006 [1,15] Adjuvant T B31/N9831/BCIG006 AC→ Pac, TCH
2006 [16] Metastatic L – Capecitabine
2009 [17] Metastatic L + AI TAnDEM None
2012 [18] Metastatic P + T CLEOPATRA Docetaxel
2013 [13] Metastatic TDM-1 EMILIA None
2013 [19] Neoadjuvant P + T NeoSphere FEC→ Pac, TCH
AI, aromatase inhibitor; AC, doxorubicin and cyclophosphamide; FEC, fluorouracil, epirubicin, cyclophosphamide, HER, human epidermal growth factor receptor;
L, lapatinib; P, pertuzumab; Pac, paclitaxel; T, trastuzumab; TCH, docetaxel, carboplatin and trastuzumab; TDM-1, ado-trastuzumab emtansine.
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have been identified in preclinical studies. Few of these
have been prospectively validated in clinical trials. There is
enough indication to suggest that some of them do limit
the effectiveness of HER2-directed therapy, particularly
when these agents are used as single agents.
Some of the proposed mechanisms for resistance to
trastuzumab include incomplete blockade of heterodi-
meric signaling or increased signaling through alternative
signal transduction pathways, including upregulation of
ligands or the receptors themselves [20], constitutive acti-
vation of the PI3K/Akt pathway due to loss of phosphat-
ase and tensin homolog (PTEN) or activating mutations
of PI3KCA or amplification of cyclin E [21,22], increased
transforming growth factor-alpha expression, and the
presence of altered forms of HER2 [23,24], which inhibits
HER2–trastuzumab interactions. Escape pathways such as
estrogen receptor (ER) or insulin-like growth factor recep-
tor signaling have also been implicated in resistance. The
data regarding PTEN loss and PI3K mutation and trastu-
zumab have been conflicting. Preclinical and smaller clin-
ical studies have suggested PTEN loss associated with
resistance to trastuzumab [25], although a larger study
(n = 1,082) did not find an impact on DFS [26].
Mechanisms for lapatinib resistance are less well es-
tablished and are hypothesized to include increased
expression of AXL, a membrane-bound receptor tyro-
sine kinase with transforming ability [27], enhanced
ER signaling through transcription factor FOXO3a
[28], and upregulation of HER3 transcription [20]. There
are discordant data with regards to PTEN loss and PI3K
mutation and use of lapatinib in preclinical and small
clinical studies [25,29].
The existence of resistance to trastuzumab and the
development of resistance after exposure to trastuzumab
are the main reasons for recurrences. Enhanced block-
ade of HER2 signaling with dual HER2 therapies may
result in decreased recurrences and ultimately improve
survival.Evidence for improved activity of combination
anti-HER2 therapy
Numerous recent and ongoing multicenter studies have
focused on the benefits and toxicity of adding single-
agent or dual HER2 targeting to chemotherapy. In the
neoadjuvant setting, almost all of the trials used a
chemotherapy backbone (taxane only or anthracycline/tax-
ane or taxane/platinum), with the exception of TBCRC 006
and a subset of patients treated on NeoSphere that only
included the targeted therapies without chemotherapy.
Using combinations of inhibitors (for example, trastuzumab
with pertuzumab or lapatinib with trastuzumab), higher re-
sponses with higher pathologic complete responses (pCRs)
have been observed (Tables 2 and 3).
Lapatinib and trastuzumab
Preclinical MCF-7/HER2 mouse xenograft studies
Trastuzumab, pertuzumab, lapatinib and gefitinib repre-
sent a group of therapeutic agents that target the HER
family by different molecular mechanisms. These drugs,
when used as single agents in the MCF7/HER2-18 xeno-
graft model, restored or enhanced sensitivity to tamoxifen.
However, tumor growth inhibition lasted only 2 to 3 months
before resistance to treatments occurred and tumor growth
resumed. Preclinical studies in animal models evaluating
the efficacy of various drug combinations have shown
that the combination HER-targeting therapy with estrogen
deprivation more effectively induced apoptosis, reduced
levels of p-AKT and mitogen-activated protein kinase,
inhibited proliferation and was capable of eradicating
HER2 overexpressing xenografts in mice [30,31]. Based on
these results, neoadjuvant studies with trastuzumab and
lapatinib together with estrogen deprivation were designed
(TBCRC 006, see below) [32].
Clinical studies
In the metastatic setting, a phase III clinical trial com-
paring lapatinib versus lapatinib and trastuzumab in 296
patients who had progressed on a trastuzumab-containing
Table 2 Published or presented multicenter neoadjuvant trials in HER2-positive disease including lapatinib



















6 weeks T and/or L→
WP × 12 weeks plus T
and/or L (n = 455)
27.6 20 46.8 NA 93% T,
66% L,
61% T + L




WP × 12 weeks→ FEC × 4
every 3 weeks plus T
and/or L throughout
(n = 121)
25 26.3 46.7 NA NR T, 69% L,




analysis between T + L vs. T,
risk ratio = 1.81, P = 0.019
NSABP
41 [36]
AC × 4→WP × 12 weeks
plus T and/or L (n = 519)
49.4 47.7 60.2 NA 77% T,
65% L,
63% T + L
Between T + L vs. T, P = 0.056;




WP × 16 weeks plus T
and/or L (n = 299)
43 29 52 NA 93% T,
66% L,
87% T + L
P = 0.11; not significant
TRIO US
B07 [38]
T and/or L × 21 days→
TCH × 6 cycles plus T
and/or L throughout
(n = 130)
47 25 52 NA 100% T,
72% L,
73% T + L
Between T + L vs. L, P = 0.02;
between T and L, P = 0.07
TBCRC
006 [32]
T and L × 12 weeks; ER +
letrozole ± G (n = 66)
NA NA NA 22 NR Single-arm study
LPT
109096 [39]
2 weeks T and/or L→ FEC
75 × 4 every 3 weeks→
WP × 12 weeks + T
and/or L throughout
(n = 100)
54 45 74 NA NR Not powered to compare
responses between arms
AC, adriamycin, cyclophosphamide; ER, estrogen receptor; FEC, fluorouracil, epirubicin, cyclophosphamide; G, goserelin; HER, human epidermal growth factor
receptor; L, lapatinib; NA, not applicable; NR, not reported; pCR, pathologic complete response; T, trastuzumab; TCH, docetaxel, carboplatin and trastuzumab;
WP, weekly paclitaxel.
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free survival (hazard ratio (HR), 0.73; 95% confidence
interval, 0.57 to 0.93; P = 0.08) and a trend towards
improved OS (HR, 0.75; 95% confidence interval, 0.53 to
1.07; P = 0.106) in patients receiving the combination [33].
This observation provided further evidence for combined
HER2 blockade as well as continued use of trastuzumab
beyond disease progression.
Six randomized neoadjuvant trials and one nonrando-
mized neoadjuvant trial as well as one adjuvant trial
have evaluated the role of dual targeted therapies withTable 3 Published or presented multicenter neoadjuvant trial






NeoSphere [19] D x 4 with T and/or P 21.5 17.7
TRYPHAENA [43] Arm A, FECPH→DPH; Arm B,
FEC→DPH; Arm C, TCHP
50.7 45.3
D, docetaxel; DPH, docetaxel, pertuzumab and trastuzumab; FEC, fluorouracil, epiru
pertuzumab and trastuzumab; HER, human epidermal growth factor receptor; NA, n
response; T, trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab and pertuzumalapatinib and trastuzumab (Table 2). Two large studies
were conducted with a taxane-only backbone with
anthracycline chemotherapy given after surgery. In the
phase III study of NeoALTTO, 455 patients received
paclitaxel with lapatinib, trastuzumab or the combination
[12]. The dual-therapy arm had significantly improved
pCR in the breast and axilla compared with trastuzumab
alone (46.8% vs. 27.6%, P = 0.0007) [12]. The pCR rates
were higher in patients with hormone receptor-negative
tumors than those of hormone receptor-positive tumors




T + P (%)
pCR breast and lymph
node combination
T + P without
chemotherapy (%)
Statistical significance
39.3 11.2 NR for pCR breast and
lymph node. For pCR breast
only between T + P and T,
P = 0.0141
51.9 NA Primary endpoint was
cardiac safety, P value NR
bicin, cyclophosphamide; FECPH, fluorouracil, epirubicin, cyclophosphamide,
ot applicable; NR, not reported; P, pertuzumab; pCR, pathologic complete
b.
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cantly better event-free survival (EFS) (86% vs. 72%; HR,
0.38; P = 0.003) and OS (94% vs. 87%; HR 0.35; P = 0.005)
compared with no pCR [34]. These results did not address
the question of whether the higher pCR rate achieved with
dual therapy translated into better EFS or OS because the
NeoALTTO trial was underpowered to detect moderate
differences in EFS and OS.
The adjuvant study ALTTO did not meet the primary
endpoint of improved DFS with the addition of lapatinib
to trastuzumab compared with trastuzumab as adjuvant
treatment for HER2-positive early breast cancer [40].
ALTTO has raised questions regarding the use of an in-
crease in pCR rate as a surrogate endpoint for improved
DFS in the adjuvant setting and the effect of dual block-
ade on long-term outcome. ALTTO demonstrates that a
large proportion of patients with HER2-positive early
breast cancer do not derive benefit with dual blockade
of lapatinib and trastuzumab. Whether a benefit exists
in a higher risk population or in a subset of patients
identified by a biomarker or a different dual blockade
should be further evaluated. APHINITY is an adjuvant
trial evaluating dual blockade of pertuzumab and trastu-
zumab versus trastuzumab in a high-risk population
(node-positive) and will further answer the question regard-
ing the benefit of dual blockade.
The CALGB 40601 trial randomized 305 patients to
receive weekly paclitaxel for 16 weeks with trastuzumab
alone or with the combination trastuzumab and lapati-
nib [37]. The pCR rate in the breast and axilla was nu-
merically higher at 52% with the combination compared
with 43% for the chemotherapy and trastuzumab arm,
but was not statistically significant. This could have been
due to underlying differences in the study population
and highlights the need to identify tumors that can benefit
with dual versus single HER2 targeting, possibly looking
at the hormone receptor differences.
Three studies have evaluated the combination of lapati-
nib and trastuzumab with similar chemotherapy backbone
of taxane followed by anthracycline-containing chemothe-
rapy. The CHER-LOB study of 121 patients demonstrated
near doubling of pCRs with dual HER2 targeting (47% vs.
25%, P = 0.019) compared with trastuzumab alone [35].
LPT 109096 included 100 patients and demonstrated a
significantly higher pCR rate for the combination (74% vs.
54%) compared with trastuzumab alone [39]. A larger ran-
domized phase III trial, NSABP B41, enrolled 529 patients
and demonstrated numerically but not statistically impro-
ved breast and lymph node pCR for the combination arm
versus trastuzumab (60.2% vs. 49.4%, P = 0.056) [36].
The TRIO US B07 study randomized 130 patients to
treatment with a chemotherapy backbone of docetaxel
and carboplatin and trastuzumab, lapatinib or both.
The primary endpoint was the pCR rate in the breastand axilla (trastuzumab 47%, lapatinib 25%, combination
52%) [38].
Finally, the nonrandomized window-of-opportunity
study TBCRC 006 treated 66 patients with the combin-
ation trastuzumab and lapatinib without a chemotherapy
backbone for 12 weeks [32]. Women with ER-positive
tumors also received letrozole (plus a luteinizing hormone-
releasing hormone agonist if premenopausal). Overall, the
pCR rate for the breast and axilla was 22% (ER-negative,
28%; ER-positive, 18%). Future studies are needed to iden-
tify a subset of HER2-positive breast cancer patients who
may not need chemotherapy and can be treated with more
complete blockade of HER receptors.
Pertuzumab and trastuzumab
One proposed cause for resistance to trastuzumab and
lapatinib is the overexpression of HER3 in response to
tyrosine kinase inhibition [20]. HER3 activation by binding
its ligand results in a conformational change of HER3 with
the formation of heterodimers with HER2. The formation
of HER2–HER3 heterodimers leads to the activation of
the PI3K signaling pathway and subsequent increase in
cell proliferation and survival. In preclinical models,
pertuzumab and trastuzumab combination demonstrated
enhanced antitumor activity when compared with each
agent alone and in tumors progressing on trastuzumab in
HER2-positive breast xenografts [41]. The studies also
demonstrated a sustained (>99 days) prevention of meta-
static tumor spread to the lungs and liver with the com-
bination in the KPL-4 xenograft model; monotherapy did
not prevent these metastases [41].
Clinical studies
In the metastatic setting, a phase III trial (CLEOPATRA)
of docetaxel and trastuzumab with or without pertuzumab
as first-line treatment for 808 patients with HER2-positive
MBC showed a significant improvement in progression-
free survival and OS with the addition of pertuzumab
[18,42]. A significant prolongation of progression-free sur-
vival was observed in the pertuzumab group (HR, 0.62;
P <0.001) with acceptable toxicity. As a result of this
study, in 2012 the US FDA approved the use of pertu-
zumab in the first-line metastatic setting. The OS was
updated in 2013; the median OS was 37.6 months in the
placebo group and was not yet reached in the pertuzumab
group (HR, 0.66; P = 0.0008) [18].
Two neoadjuvant phase II studies have evaluated the
addition of pertuzumab to various chemotherapy back-
bones (Table 3). NeoSphere is a four-arm randomized
multicenter, open-label, phase 2 study of neoadjuvant
therapy in 417 patients and compares single-agent trastu-
zumab or pertuzumab with docetaxel or the combination
of trastuzumab and pertuzumab with or without docetaxel
for four cycles [19]. The patients given pertuzumab and
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in breast pCR compared with the docetaxel and trastuzu-
mab only arm (46% vs. 29%, P = 0.0141) as well as in the
breast and lymph node pCR (39.3% vs. 21.5%). Consistent
with previous studies, a lower pCR rate was noted for hor-
mone receptor-positive patients compared with hormone
receptor-negative tumors (26% vs. 63%). The combination
targeted therapies only arm also had a 16.8% breast-only
pCR rate and an 11.2% breast and lymph node pCR
rate [19].
TRYPHAENA, an open-label, phase II study, random-
ized 225 patients to neoadjuvant chemotherapy with either:
fluorouracil, epirubicin and cyclophosphamide concurrent
with combination trastuzumab and pertuzumab for three
cycles followed by docetaxel and the combination for three
cycles (Arm A); with fluorouracil, epirubicin and cyclo-
phosphamide alone for three cycles followed by docetaxel
with the combination for three cycles (Arm B); or with
docetaxel, carboplatin and trastuzumab with pertuzumab
for six cycles (Arm C) [43]. The pCRs in the breast and
lymph nodes were 50.7% (Arm A), 45.3% (Arm B) and
51.9% (Arm C). The study was not intended to evaluate
the superiority of any trial arm and the combination of
trastuzumab and pertuzumab was generally well tolerated.
In 2013 the US FDA provided an accelerated approval
for the use of pertuzumab in combination with trastuzu-
mab and chemotherapy for the neoadjuvant treatment of
HER2-positive locally advanced, inflammatory or early-
stage breast cancer (either >2 cm in diameter or node-
positive) as part of complete treatment regimen for early
breast cancer [44]. This approval was based on the results
of phase II NeoSphere [19] and was supported by phase II
study TRYPHAENA trials [43], added to the fact that
there was an already demonstrated improvement in OS in
the metastatic setting (based on the CLEOPATRA study
[18]). This represented the first regimen approved by the
US FDA specifically for neoadjuvant treatment of breast
cancer, although full approval will depend on additional
data related to EFS in the adjuvant setting, which will be
based on the data from the APHINITY trial (expected
around 2016 or 2017; NCT01358877).
Dual blockade with antibody–drug conjugate and
targeted therapy
Even with dual blockade, there is a subset of patients that
do not achieve pCR or have early progression [19,42,43]. In
the hope of improving efficacy, studies of ADC-containing
dual blockade are ongoing.
T-DM1 and pertuzumab
Preclinical studies
In MDA-175 cells, the combination of T-DM1 and per-
tuzumab showed enhanced antiproliferative activity and
induction of apoptosis compared with either agent alone[45]. In Calu-3, BT-474 and SK-BR-3 cells, T-DM1 was
more active than pertuzumab and the combination was
more potent than the single drugs. Previous studies have
noted that the presence of the HER3 ligand heregulin
(NRG-1β) can reduce the cytotoxic activity of T-DM1 in
a subset of breast cancer cell lines. The addition of pertu-
zumab fully restored the apoptotic response to T-DM1,
providing additional evidence for the rationale of combin-
ing pertuzumab and T-DM1 [45].
The combination of T-DM1 and pertuzumab in vivo
in the KPL-4 breast tumor xenografts resulted in statisti-
cally significant inhibition of tumor growth as compared
with the single-agent treatment group. Sustained tumor
growth inhibition was also seen for the duration of the
study (88 days) compared with 40 days with T-DM1
alone [45].Clinical studies
A global phase Ib/II study was conducted to investigate
the safety and efficacy of T-DM1 and pertuzumab. The
phase Ib results demonstrated acceptable tolerability and
promising efficacy (response rate 44.4%) in heavily pre-
treated MBC patients [45]. The MARIANNE trial is a
phase III study in first-line HER2-positive MBC patients
that randomizes patients to receive trastuzumab plus a
taxane versus T-DM1 plus placebo versus T-DM1 plus
pertuzumab (results expected late 2014 or early 2015;
NCT01120184).T-DM1 and lapatinib
Preclinical studies
Single-agent trastuzumab, lapatinib or T-DM1 and the
combination of trastuzumab plus lapatinib and the com-
bination of T-DM1 plus lapatinib were studied in vivo in
the BT474-me breast cancer cell line (J Chang, unpub-
lished data). Tumors treated with single-agent T-DM1
and those treated with the combination of trastuzumab
plus lapatinib showed a similar reduction in tumor size.
The most significant tumor size reduction was observed
in the group treated with the combination of TDM-1
plus lapatinib, where tumor regression was observed in
the first 2 days and was significantly superior to the re-
gression observed in the tumors treated with trastuzumab
plus lapatinib combination (Figure 1a).
BT474 and SKBR3 cell lines were treated with single-
agent trastuzumab, lapatinib, or T-DM1 or with the com-
bination of lapatinib and T-DM1 (J Chang, unpublished
data). Proliferation was reduced by lapatinib and lapatinib
combination in both cell lines (Figure 1b). Single-agent
trastuzumab, single-agent TDM-1 and the combination of
TDM-1 plus lapatinib demonstrated significantly induced
apoptosis in both cell lines (Figure 1c). These data support




Figure 1 (See legend on next page.)
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Figure 1 Dual blockade with antibody–drug conjugate and targeted therapy. (a) SCID Beige mice were injected with 1 million cells per
mouse of the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line BT474-m1. These animals were
randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine
(TDM1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily).
Tumor volume fold-change will be measured twice weekly post-treatment. (b,c) BT474 and SKBR3 HER2-positive cell lines were treated with the
following: vehicle control; TDM1 (1 mg/ml); trastuzumab (10 mg/ml) + lapatinib (10 mM); or TDM1 (1 mg/ml) + lapatinib (10 mM). Cells were assessed
for proliferation and apoptosis post-treatment. *Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of
different groups, P < 0.05; T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.
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for synergism with combinatorial treatments.
Clinical studies
Based on the preclinical data, a phase Ib study of lapati-
nib in combination with T-DM1 and nab-paclitaxel is
currently ongoing. In a 3 + 3 study design, the maximum
tolerated dose was found to be T-DM1 3.6 mg/kg intra-
venously every 3 weeks plus lapatinib 750 mg/daily or-
ally along with nab-paclitaxel 80 mg/m2 intravenously
weekly [ClinicalTrials.gov: NCT02073916].
Newer tyrosine kinase inhibitors of HER2
Studies are ongoing into the combination of afatinib and
trastuzumab or the combination of neratinib and trastu-
zumab in the metastatic and neoadjuvant settings.
Trastuzumab and afatinib
Afatinib is a tyrosine kinase inhibitor with activity against
HER2 and endothelial growth factor receptor. In a phase
II trial of patients with HER2-positive MBC that had pro-
gressed following trastuzumab, a 10% response rate (4/41
patients) was observed with afatinib, demonstratingTable 4 Pathologic complete response with dual HER2 regime
receptor-positive subsets of HER2 positive breast cancer: an e
Study pCR breast and lymph
node combination T + L




NeoALTTO [12,34] 46.8 61
CHER-LOB [35] 46.7 41
NSABP 41 [36] 60.2 55
CALGB 40601 [37] 52 66
TRIO US B07 [38] 52 67
NeoSphere [19,32] 39.3 63
TRYPHAENA [43] 50.7 FECPH→DPH 79
51.9 TCHP 83
LPT 109096 [39] 74 NR
DPH, docetaxel, pertuzumab and trastuzumab; ER, estrogen receptor; FECPH, fluoro
human epidermal growth factor receptor; L, lapatinib; NR, not reported; P, pertuzum
carboplatin, trastuzumab and pertuzumab.the activity of this agent in this refractory metastatic
setting [46].
Trastuzumab and neratinib
Neratinib is an oral irreversible inhibitor of endothelial
growth factor receptor and HER2 tyrosine kinases. A
phase II trial of single-agent neratinib showed a 24%
response rate in MBC patients who had progression
following trastuzumab and a 56% response rate as first-
line therapy [47]. Diarrhea occurred in 30% of patients
with prior trastuzumab treatment and 13% of patients
with no prior trastuzumab treatment [47].
Different subsets of HER2-positive breast cancers:
hormone receptor-positive and hormone
receptor-negative subsets
Several completed neoadjuvant trials have demonstrated
significant differences in the rates of pCR among hor-
mone receptor-positive and hormone receptor-negative
subsets, with higher pCR rates (at least twice as high) in
the hormone receptor-negative subsets (Table 4). The
highest pCR rates were seen in the HER2-enhanced sub-
set, with the lowest response rates noted in the luminal
subsets [37]. The duration of neoadjuvant therapy isn in hormone receptor-negative versus hormone
xploratory comparison
R breast and lymph node
mbination T + L or T + P
-negative subset (%)
pCR breast and lymph node











uracil, epirubicin, cyclophosphamide, pertuzumab and trastuzumab; HER,
ab; pCR, pathologic complete response; T, trastuzumab; TCHP, docetaxel,
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http://breast-cancer-research.com/content/16/1/419relatively short and recent studies have shown pCR correl-
ation with progression-free survival in hormone receptor-
negative subsets rather than hormone receptor-positive
subsets, so the true benefit of dual therapy in hormone
receptor-positive patients should be assessed with longer
term therapy. This benefit is currently being assessed
with an extension study of lapatinib plus trastuzumab
with or without endocrine therapy (HELEX) TBCRC 023
[ClinicalTrials.gov: NCT00999804].Conclusion
Therapies directed at HER2 establish a successful treat-
ment paradigm, but de novo and acquired resistance
exist. With the help of a neoadjuvant model, many stud-
ies have demonstrated that single-agent HER2-targeted
therapies are efficacious but response is incomplete.
Large randomized clinical trials have also demonstrated
that dual HER2 targeted combinations with trastuzu-
mab/lapatinib and trastuzumab/pertuzumab are syner-
gistic. Recently, the ADC T-DM1 has been approved for
the treatment of HER2-overexpressing MBC. Combination
of dual HER2-targeted treatments with T-DM1 and lapati-
nib or pertuzumab may demonstrate improved efficacy in
patients. The results of the ALTTO trial highlight the chal-
lenge of determining which patients need multiple targeted
therapies. In the future, correlative science embedded
within the clinical trials will be invaluable in developing
personalized therapy. Studies aimed at characterizing the
different genetic alterations associated with resistance to
HER2-directed therapies may lead to the discovery of new
targets that may overcome resistance.Note: This article is part of a series on ‘Recent advances in
breast cancer treatment’, edited by Jenny Chang. Other articles
in this series can be found at http://breast-cancer-research.
com/series/treatment.Abbreviations
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